<?xml version="1.0" encoding="utf-8"?>
<journal>
<title>Vaccine Research</title>
<title_fa>Vaccine Research</title_fa>
<short_title>vacres</short_title>
<subject>Medical Sciences</subject>
<web_url>http://vacres.pasteur.ac.ir</web_url>
<journal_hbi_system_id>1</journal_hbi_system_id>
<journal_hbi_system_user>admin</journal_hbi_system_user>
<journal_id_issn>2383-2819</journal_id_issn>
<journal_id_issn_online>2423-4923</journal_id_issn_online>
<journal_id_pii></journal_id_pii>
<journal_id_doi>10.61186/vacres</journal_id_doi>
<journal_id_iranmedex></journal_id_iranmedex>
<journal_id_magiran></journal_id_magiran>
<journal_id_sid></journal_id_sid>
<journal_id_nlai></journal_id_nlai>
<journal_id_science></journal_id_science>
<language>en</language>
<pubdate>
	<type>jalali</type>
	<year>1400</year>
	<month>3</month>
	<day>1</day>
</pubdate>
<pubdate>
	<type>gregorian</type>
	<year>2021</year>
	<month>6</month>
	<day>1</day>
</pubdate>
<volume>8</volume>
<number>1</number>
<publish_type>online</publish_type>
<publish_edition>1</publish_edition>
<article_type>fulltext</article_type>
<articleset>
	<article>


	<language>en</language>
	<article_id_doi></article_id_doi>
	<title_fa></title_fa>
	<title>Comparative Study of AEFI of Hepatitis B Vaccine between Iran Ministry of Health CDC and VAERS Data during 2015 to 2017</title>
	<subject_fa>Vaccine development, efficacy and safety evaluation</subject_fa>
	<subject>Vaccine development, efficacy and safety evaluation</subject>
	<content_type_fa>پژوهشي</content_type_fa>
	<content_type>Research</content_type>
	<abstract_fa></abstract_fa>
	<abstract>&lt;strong&gt;Introduction:&lt;/strong&gt; Hepatitis B Vaccine (HBV) is a safe and effective vaccine that is nowadays recommended for all infants at birth as well as adults who could be exposed to hepatitis B virus. HBV can provide lifetime protection against hepatitis B virus infection. Despite its highly effective disease prevention, HBV can also cause adverse effects for the vaccinated population. A vast majority of Iran&amp;#39;s population are vaccinated with recombinant hepatitis B vaccine (rHBV) which is manufactured by the Production and Research Complex of Pasteur Institute of Iran. &lt;strong&gt;Methods:&amp;nbsp; &lt;/strong&gt;The reported adverse events of rHBV, obtained from Diseases Management Center of Iran&amp;rsquo;s Ministry of Health were compared with those in The Vaccine Adverse Event Reporting System (VAERS, a United States program for vaccine safety, co-managed by the U.S. Centers for Disease Control and Prevention) during 2015 to 2017. &lt;strong&gt;Results:&lt;/strong&gt; The most common adverse events after administration of rHBV, manufactured by Pasteur Institute of Iran was injection site reactions and no life threatening adverse event was observed. &lt;strong&gt;Conclusion:&lt;/strong&gt; Despite reports by VAERS indicating that HBV can cause adverse events and even death in the United States, no such adverse effects were observed in rHBV manufactured in Iran.</abstract>
	<keyword_fa></keyword_fa>
	<keyword>AEFI, rHBV, VAERS, CDC, Pasteur Institute of Iran</keyword>
	<start_page>52</start_page>
	<end_page>59</end_page>
	<web_url>http://vacres.pasteur.ac.ir/browse.php?a_code=A-10-1-67&amp;slc_lang=en&amp;sid=1</web_url>


<author_list>
	<author>
	<first_name>Hamidreza </first_name>
	<middle_name></middle_name>
	<last_name>Hozouri</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code></code>
	<orcid>0000-0002-1912-9395</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Department of Quality Management, Pasteur Institute of Iran, Tehran, Iran. Viral Vaccine Research Center, Pasteur Institute of Iran, Tehran, Iran.</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Alireza </first_name>
	<middle_name></middle_name>
	<last_name>Shamsian</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code></code>
	<orcid>Alireza Shamsian</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Faculty of Pharmacy, Azad University, Tehran, Iran</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Mohammadreza </first_name>
	<middle_name></middle_name>
	<last_name>Aghasadeghi</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code></code>
	<orcid>0000-0003-2186-0774</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>3Viral Vaccine Research Center, Pasteur Institute of Iran, Tehran, Iran. </affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Delaram </first_name>
	<middle_name></middle_name>
	<last_name>Doroud</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>d_doroud@pasteur.ac.ir</email>
	<code></code>
	<orcid>0000-0003-4167-9921</orcid>
	<coreauthor>Yes
</coreauthor>
	<affiliation>Viral Vaccine Research Center, Pasteur Institute of Iran, Tehran, Iran. Production and Research Complex, Pasteur Institute of Iran, Tehran, Iran.</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


</author_list>


	</article>
</articleset>
</journal>
